Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL

Starting soon · Phase 3 · Has a placebo group

Conditions studied: Acute Coronary Syndrome (ACS)

In brief

CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in participants with elevated Lp(a) and recent acute coronary syndrome (ACS).

Key facts

Study ID

NCT07625306

Run by

Novartis Pharmaceuticals

People needed

240

Starts

2026-08-31

Expected to finish

2028-12-07

Last updated by the study team

2026-06-04

Who can join

Age: 18 and older, up to 79. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Lp(a) ≥ 150 nmol/L
• Within 10 days of hospitalization for ACS event and meets all of the following criteria:
• Clinical syndrome consistent with spontaneous cardiac ischemia
• Diagnosis of ACS: ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI)

You may not qualify if…

• Uncontrolled hypertension
• Heart failure New York Heart Association (NYHA) class IV
• History of malignancy of any organs
• History of hemorrhagic stroke or other major bleeding
• Platelet count ≤ LLN
• Active liver disease or hepatic dysfunction
• Significant kidney disease
• Contraindication for CCTA or severe contrast allergy
• Pregnant or nursing women
• Other protocol-defined inclusion/exclusion criteria may apply

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.